Table 3.

Adverse events prior to surgery in 30 patients during CRT plus apatinib treatment

Adverse events	Total	Grade 1	Grade 2	Grade 3	Grade 4/5
Hematologic, No. (%)
Leukopenia	23 (76.7)	5 (16.7)	13 (43.3)	5 (16.7)	0 (0.0)
Thrombocytopenia	17 (56.7)	14 (46.7)	2 (6.7)	1 (3.3)	0 (0.0)
Neutropenia	15 (50.0)	7 (23.3)	6 (20.0)	2 (6.7)	0 (0.0)
Non-hematologic, No. (%)
Nausea	20 (66.7)	10 (33.3)	8 (26.7)	2 (6.7)	0 (0.0)
Fatigue	19 (63.3)	14 (46.7)	5 (16.7)	0 (0.0)	0 (0.0)
Abnormal liver function	16 (53.3)	15 (50.0)	1 (3.3)	0 (0.0)	0 (0.0)
Vomiting	11 (36.7)	7 (23.3)	2 (6.7)	2 (6.7)	0 (0.0)
Hypertension	10 (33.3)	8 (26.7)	2 (6.7)	0 (0.0)	0 (0.0)
Radioactive esophagitis	7 (23.3)	5 (16.7)	2 (6.7)	0 (0.0)	0 (0.0)
Diarrhea	3 (10.0)	2 (6.7)	0 (0.0)	1 (3.3)	0 (0.0)
Hand-foot syndrome	1 (3.3)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)

CRT, chemoradiotherapy.